Browse views: by Year, by Function, by GLF, by Subfunction, by Conference, by Journal

Evasion mechanisms to Igf1r inhibition in rhabdomyosarcoma

Abraham, Jinu, Prajapati, Suresh, Nishijo, Koichi, Schaffer, Beverly S, Taniguchi, Eri, Kilcoyne, Aoife, McCleish, Amanda T, Zarzabal, Lee Ann, Michalek, Joel E, Nelon, Laura D, Giles, Francis G, Efstratiadis, Argiris, LeGallo, Robin D, Nowak, Brent M, Rubin, Brian P, Keller, Charles and Jeay, Sebastien (2011) Evasion mechanisms to Igf1r inhibition in rhabdomyosarcoma. Molecular Cancer Therapeutics, 10 (4). pp. 697-707. ISSN 1535-7163

Abstract

Inhibition of the insulin-like growth factor 1 receptor (Igf1r) is an approach being taken in clinical trials to overcome the dismal outcome for metastatic alveolar rhabdomyosarcoma (ARMS), an aggressive muscle cancer of children and young adults. In our study, we address the potential mechanism(s) of Igf1r inhibitor resistance that might be anticipated for patients. Using a genetically engineered mouse model of ARMS, validated for active Igf1r signaling, we show that the prototypic Igf1r inhibitor NVP-AEW541 can inhibit cell growth and induce apoptosis in vitro in association with decreased Akt and Mapk phosphorylation. However, drug resistance in vivo is more common and is accompanied by Igf1r overexpression, Mapk reactivation, and Her2 overexpression. Her2 is found to form heterodimers with Igf1r in resistant primary tumor cell cultures, and stimulation with Igf2 leads to Her2 phosphorylation. The Her2 inhibitor lapatinib cooperates with NVP-AEW541 to reduce Igf1r phosphorylation and to inhibit cell growth even though lapatinib alone has little effect on growth. These results point to the potential therapeutic importance of simultaneous targeting of Igf1r and Her2 to abrogate resistance.

Item Type: Article
Related URLs:
Additional Information: author can archive post-print (ie final draft post-refereeing); Authors final version may be deposited on institutional website/ repository if required by institution
Keywords: IGF, resistance, Rhabdomyosarcoma, Insulin-like growth factor receptor 1
Related URLs:
Date Deposited: 13 Oct 2015 13:16
Last Modified: 13 Oct 2015 13:16
URI: https://oak.novartis.com/id/eprint/3191

Search

Email Alerts

Register with OAK to receive email alerts for saved searches.